Opinion
Video
Author(s):
Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.
Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers
Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH
Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations
Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD
China’s NMPA Approves Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer
TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer